Thomas Tuschl

Co-Founder at Alnylam Pharmaceuticals, Inc.

Thomas Tuschl

Thomas Tuschl

Co-Founder at Alnylam Pharmaceuticals, Inc.

Overview
Career Highlights

Alnylam Pharmaceuticals, Inc.

RelSci Relationships

884

Number of Boards

2

Birthday

06/01/1966

Age

53

Relationships
RelSci Relationships are individuals Thomas Tuschl likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Co-Founder at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Co-Founder at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Co-Founder at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Founder at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Chief Executive Officer at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

President at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

President-Research & Development at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Executive Vice President, Chief Legal Officer & Secretary at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Chief Medical Officer at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Paths to Thomas Tuschl
Potential Connections via
Relationship Science
You
Thomas Tuschl
Co-Founder at Alnylam Pharmaceuticals, Inc.
Career History
Co-Founder
2002 - Current

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Head of the Laboratory, RNA Molecular Biology
Current

The Rockefeller University is a world-renowned center for research and graduate education in the biomedical sciences, chemistry, bioinformatics and physics. The university’s 72 laboratories conduct both clinical and basic research and study a diverse range of biological and biomedical problems with the mission of improving the understanding of life for the benefit of humanity. Founded in 1901 by John D. Rockefeller, the Rockefeller Institute for Medical Research was the country’s first institution devoted exclusively to biomedical research. The Rockefeller University Hospital was founded in 1910 as the first hospital devoted exclusively to clinical research. In the 1950s, the institute expanded its mission to include graduate education and began training new generations of scientists to become research leaders around the world. In 1965, it was renamed The Rockefeller University. The university is supported by a combination of government and private grants and contracts, private philanthropy and income from the endowment. Since its founding, The Rockefeller University has embraced an open structure to encourage collaboration between disciplines and empower faculty members to take on high-risk, high-reward projects. No formal departments exist, bureaucracy is kept to a minimum and scientists are given resources, support and unparalleled freedom to follow the science wherever it leads. This unique approach to science has led to some of the world’s most revolutionary contributions to biology and medicine. Throughout Rockefeller’s history, 24 of its scientists have won Nobel Prizes, 21 have won Lasker Awards and 20 have garnered the National Medal of Science, the highest science award given by the United States. For more than 100 years, The Rockefeller Hospital has served as an essential link between laboratory investigation and bedside observation, as patients are participants in clinical studies building on basic research findings from Rockefeller laboratories. This continuous spectrum of research allows for in-depth study of the basis of disease detection, prevention and observation. The David Rockefeller Graduate Program is based on the concept of learning science by doing science, and is custom tailored to its individual students and attracts a diverse group of exceptional scientists from around the world. The university also offers one of the nation’s top M.D.-Ph.D. programs with neighboring Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College. In addition to the graduate program, there are other learning/training opportunities available, including postdoctoral research, fellowships for the Center for Studies in Physics and Biology and the Clinical Scholars Program, a master's degree for recent M.D. or M.D.-Ph.D. recipients to begin careers in patient-oriented research

Investigator
Current

The Howard Hughes Medical Institute (HHMI) is a nonprofit medical research organization that ranks as one of the nation’s largest philanthropies. HHMI plays a prominent role in advancing biomedical research and science education in the United States. Founded in 1953 by aviator and industrialist Howard R. Hughes, HHMI is headquartered in Chevy Chase, Maryland, and employs more than 3,000 individuals across the U.S. HHMI has an endowment of $16.1 billion of which the Institute spent $800 million for research and distributed $119 million in grant support for science education in fiscal year 2012

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Thomas Tuschl. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Thomas Tuschl's profile does not indicate a business or promotional relationship of any kind between RelSci and Thomas Tuschl.
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/person/thomas-tuschl-82092980
  • https://relationshipscience.com/person/thomas-tuschl-82092980